Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

SIM0500

- PMLiVE

J&J’s Darzalex combination treatment for untreated multiple myeloma recommended by NICE

Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer

- PMLiVE

AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo

Rinvoq is the first and only systemic medication approved in the EU for NSV

- PMLiVE

Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA

Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma

- PMLiVE

AbbVie to acquire Apogee Therapeutics in $10.9bn deal

The acquisition includes clinical-stage candidates for atopic dermatitis and asthma

- PMLiVE

Roche and Nurix Therapeutics to partner in $2.3bn deal

The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology

- PMLiVE

Legend Biotech appoints new group of scientific advisors

The company is focused on CAR-T cell therapy to treat multiple myeloma

- PMLiVE

Allergan Aesthetics launches Skin Quality Index for aesthetic consultations

Spanning four dimensions of skin health, the framework introduces 15 terms and definitions

- PMLiVE

Bristol Myers Squibb evolves and expands multiple myeloma programme

Created in 2016, the Standing in the Gaap programme aims to advance more equitable care

- PMLiVE

Gilead to acquire Arcellx in deal worth $7.8bn

The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma

- PMLiVE

Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma

Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable

- PMLiVE

AbbVie reaches agreement for affordable prescription drugs with US government

The pharma company has also pledged a $100bn investment in US infrastructure over the next decade

- PMLiVE

J&J receives positive NICE recommendation for multiple myeloma treatment

The treatment is approved for use within the NHS in England and Wales

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links